Key result
Anticoagulant prophylaxis, predominantly enoxaparin, safely prevented thrombosis, though warfarin and some forms of heparin were associated with bleeding events.
Why the study?
Patients undergoing bariatric surgery for severe obesity are at risk of venous thromboembolism and pulmonary embolism, prompting the evaluation of anticoagulant prophylaxis safety and effectiveness.
Does anticoagulant prophylaxis safely and effectively prevent venous thromboembolism in patients undergoing bariatric surgery?
Cohort (n=1,497)
No
Does anticoagulant prophylaxis safely and effectively prevent venous thromboembolism in patients undergoing bariatric surgery?
Enoxaparin is a safe and effective option for VTE prophylaxis in bariatric surgery patients, whereas warfarin and certain heparins may carry a higher risk of bleeding.
Answers are grounded in this paper and cite their sources.
Supports heightened post-bariatric VTE vigilance; hypothesis-generating in Level 3 cohort data.
Background: The obesity epidemic is a major challenge in many high-income and lower-middle-income countries, creating a need for urgent interventions to reverse the trends. One of the common interventions adopted to address the problem in affected patients is bariatric surgery which aims to modify the digestive system. However, patients undergoing this treatment for severe cases of obesity may be at risk of venous thromboembolism (VTE) and pulmonary embolism, which significantly increase the risk of morbidity and mortality. A blood clot (thrombus) forms in a blood vessel and travels through the bloodstream until it lodges in a smaller channel, causing an embolism. As such, anticoagulants are regularly administered to prevent VTE. Objectives: We aimed to evaluate the safety and effectiveness of anticoagulant prophylaxis in patients undergoing bariatric surgery. Materials and Methods: We conducted a retrospective cohort study that examined patient data captured through an electronic medical system at King Saud University Medical City in Riyadh, Saudi Arabia, between January 2016 and December 2020. The primary outcome measures were the occurrence of thrombosis and major bleeding. Results: Our study findings revealed that the most preferred anticoagulant was enoxaparin, administered in 90.2% of the cases, which is the most effective and safe tested on 1497 patients. The records were reported cases of thrombotic events; the frequency of such cases was too low and statistically insignificant for enoxaparin doses ( P = 0 .369 ). However, the results showed a significant association between bleeding events, warfarin use, and some forms of heparin ( P = 0 .014 ). Conclusion: Our research shows that anticoagulant prophylaxis safely and successfully prevents VTE in patients undergoing bariatric surgery. It is advised to keep an eye out for bleeding episodes in the patients, particularly during the first week following bariatric surgery and when taking anticoagulants.
No takes yet. Share an insight, caveat, or question.
Ayyashi et al. (2024) conducted a cohort in Obesity requiring bariatric surgery (n=1,497). Anticoagulant prophylaxis (predominantly enoxaparin) was evaluated on Occurrence of thrombosis and major bleeding (p=0.369 for thrombosis; 0.014 for bleeding). Anticoagulant prophylaxis, predominantly enoxaparin, safely prevented thrombosis, though warfarin and some forms of heparin were associated with bleeding events.
Synapse has enriched 10 related papers. Consider them for comparative context: